PMID- 26950284
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20161230
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
VI  - 18
IP  - 3
DP  - 2016 Mar
TI  - Effect of Metformin on Fibroblast Growth Factor-21 Levels in Patients with Newly 
      Diagnosed Type 2 Diabetes.
PG  - 120-6
LID - 10.1089/dia.2015.0261 [doi]
AB  - BACKGROUND: Fibroblast growth factor (FGF)-21 is an important regulator of 
      glucose metabolism. In the present study, we investigated whether plasma levels 
      of FGF-21 changed in patients with newly diagnosed type 2 diabetes mellitus 
      (T2DM) and assessed the effects of metformin treatment on plasma FGF-21 levels. 
      MATERIALS AND METHODS: The plasma FGF-21 levels and the metabolic parameters of 
      226 patients with newly diagnosed T2DM and 100 sex- and age-matched normal 
      glycemic tolerant (NGT) controls were measured. Seventy-four patients among of 
      the 226 patients with T2DM were treated with metformin throughout the 12-week 
      study period. The fasting plasma FGF-21 and high-sensitivity C-reactive protein 
      (hs-CRP) levels were measured using enzyme-linked immunosorbent assay kits. 
      RESULTS: The patients with T2DM had significantly higher fasting plasma FGF-21 
      levels (302.2 pg/mL [range, 201.3-454.4 pg/mL] vs. 104.5 pg/mL [range, 
      71.6-185.6 pg/mL]; P < 0.00) and hs-CRP levels (2.63 +/- 2.81 mg/L vs. 
      1.58 +/- 2.16 mg/L; P < 0.00) than the NGT subjects. The fasting plasma hs-CRP and 
      FGF-21 levels were significantly decreased in the T2DM group after metformin 
      treatment compared with pretreatment (respectively, 2.56 +/- 1.75 mg/L vs. 
      3.28 +/- 1.89 mg/L [P < 0.05] and 232.6 pg/mL [range, 154.3-307.8 pg/mL] vs. 
      313.9 pg/mL [range, 227.7-474.2 pg/mL] [P < 0.01]). CONCLUSIONS: In patients with 
      T2DM, the plasma FGF-21 levels are increased but are significantly decreased 
      after metformin treatment. Metformin may play a role in reducing the FGF-21 
      levels in patients with T2DM, likely through the amelioration of glucose-lipid 
      metabolism and inflammation.
FAU - Fan, Hui
AU  - Fan H
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University , Beijing, People's Republic of China .
FAU - Sun, XiaoMeng
AU  - Sun X
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University , Beijing, People's Republic of China .
FAU - Zhang, Heng
AU  - Zhang H
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University , Beijing, People's Republic of China .
FAU - Liu, Jia
AU  - Liu J
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University , Beijing, People's Republic of China .
FAU - Zhang, PengRui
AU  - Zhang P
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University , Beijing, People's Republic of China .
FAU - Xu, Yuan
AU  - Xu Y
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University , Beijing, People's Republic of China .
FAU - Pan, QingRong
AU  - Pan Q
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University , Beijing, People's Republic of China .
FAU - Wang, Guang
AU  - Wang G
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University , Beijing, People's Republic of China .
LA  - eng
PT  - Journal Article
DEP - 20160307
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (fibroblast growth factor 21)
RN  - 62031-54-3 (Fibroblast Growth Factors)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 9100L32L2N (Metformin)
SB  - IM
CIN - Diabetes Technol Ther. 2016 Mar;18(3):113-4. PMID: 26983024
MH  - Adult
MH  - Aged
MH  - C-Reactive Protein/analysis
MH  - Case-Control Studies
MH  - China
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/physiopathology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Fibroblast Growth Factors/*antagonists & inhibitors/blood
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin Resistance
MH  - Male
MH  - Metformin/*therapeutic use
MH  - Middle Aged
MH  - Severity of Illness Index
MH  - Up-Regulation/*drug effects
EDAT- 2016/03/08 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/03/08 06:00
PHST- 2016/03/08 06:00 [entrez]
PHST- 2016/03/08 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 10.1089/dia.2015.0261 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2016 Mar;18(3):120-6. doi: 10.1089/dia.2015.0261. Epub 
      2016 Mar 7.